18:58 , Jul 13, 2018 |  BC Week In Review  |  Company News

NICE does not recommend Roche's ocrelizumab for primary progressive MS

The U.K.'s NICE said in an appraisal consultation it does not recommend the use of Ocrevus ocrelizumab from Roche (SIX:ROG; OTCQX:RHHBY) to treat primary progressive multiple sclerosis (MS) with imaging features characteristic of inflammatory activity...
17:56 , Jun 22, 2018 |  BC Week In Review  |  Company News

NICE recommends Roche's Ocrevus for relapse-remitting multiple sclerosis

The U.K.'s NICE issued a final appraisal determination (FAD) recommending the use of Ocrevus ocrelizumab from Roche (SIX:ROG; OTCQX:RHHBY) to treat relapse-remitting multiple sclerosis. In January, the European Commission approved the second-generation humanized mAb against CD20...
18:19 , Jun 15, 2018 |  BC Week In Review  |  Clinical News

Molecular Templates' NHL candidate shows higher response rates with low baseline Rituxan levels

Molecular Templates Inc. (NASDAQ:MTEM) reported Phase I data from 10 evaluable relapsed or refractory diffuse large B cell lymphoma (DLBCL) patients with low serum Rituxan rituximab levels at baseline showing that MT-3724 led to an...
18:18 , Jun 15, 2018 |  BC Week In Review  |  Clinical News

FDA approves Rituxan for pemphigus vulgaris

FDA approved Genentech Inc.’s Rituxan rituximab to treat moderate to severe pemphigus vulgaris. The Roche (SIX:ROG; OTCQX:RHHBY) unit said Rituxan is the first biologic approved by the agency for the disease and the first FDA-approved...
00:05 , Jun 14, 2018 |  BC Extra  |  Preclinical News

Cellectis unveils safety CAR construct

In an effort to mitigate adverse effects associated with CAR T therapies, researchers at Cellectis S.A. (NASDAQ:CLLS; Euronext:ALCLS) and its collaborator Allogene Therapeutics Inc. (South San Francisco, Calif.) developed an integrated safeguard for CAR T...
18:26 , Jun 13, 2018 |  BC Innovations  |  Distillery Techniques

Assays and screens

TECHNOLOGY: Diagnostic assays A microfluidics-based method for detecting tumor cells in urine could help diagnose bladder cancer. The assay involves two steps: adding patient urine samples to a microfluidics device consisting of a chamber for directional...
18:31 , Jun 8, 2018 |  BC Week In Review  |  Clinical News

TG Therapeutics reports Phase II data for umbralisib in CLL

TG Therapeutics Inc. (NASDAQ:TGTX) said once-daily oral umbralisib (TGR-1202) led to nodal reductions in nearly all patients evaluable for response, including three patients with complete resolution of nodal disease, in a Phase II trial to...
23:31 , Jun 7, 2018 |  BC Extra  |  Company News

FDA approves Rituxan for pemphigus vulgaris

FDA approved Genentech Inc.’s Rituxan rituximab to treat moderate to severe pemphigus vulgaris. The Roche (SIX:ROG; OTCQX:RHHBY) unit said Rituxan is the first biologic approved by the agency for the disease and the first FDA-approved...
17:49 , Jun 1, 2018 |  BC Week In Review  |  Clinical News

Molecular Templates reports Phase I data for NHL candidate

Molecular Templates Inc. (NASDAQ:MTEM) reported interim data from 24 evaluable patients with relapsed or refractory diffuse large B cell lymphoma (DLBCL) in a Phase I trial showing that MT-3724 led to an overall response rate...
17:02 , May 25, 2018 |  BC Week In Review  |  Clinical News

Genmab's Arzerra misses in Phase III for indolent NHL

Genmab A/S (CSE:GEN) said Arzerra ofatumumab plus Treanda bendamustine missed the primary endpoint of improving progression-free survival (PFS) in the Phase III COMPLEMENT A+B trial to treat indolent B cell non-Hodgkin's lymphoma (NHL). The company...